HomeCompareMDGEF vs EQR

MDGEF vs EQR: Dividend Comparison 2026

MDGEF yields 77.22% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MDGEF wins by $1.42M in total portfolio value
10 years
MDGEF
MDGEF
● Live price
77.22%
Share price
$2.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.46M
Annual income
$412,841.82
Full MDGEF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — MDGEF vs EQR

📍 MDGEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDGEFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDGEF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDGEF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDGEF
Annual income on $10K today (after 15% tax)
$6,563.71/yr
After 10yr DRIP, annual income (after tax)
$350,915.55/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, MDGEF beats the other by $347,668.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDGEF + EQR for your $10,000?

MDGEF: 50%EQR: 50%
100% EQR50/50100% MDGEF
Portfolio after 10yr
$752.5K
Annual income
$208,330.71/yr
Blended yield
27.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MDGEF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-23.8
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDGEF buys
0
EQR buys
0
No recent congressional trades found for MDGEF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDGEFEQR
Forward yield77.22%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$1.46M$40.5K
Annual income after 10y$412,841.82$3,819.61
Total dividends collected$1.27M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: MDGEF vs EQR ($10,000, DRIP)

YearMDGEF PortfolioMDGEF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$18,422$7,722.01$11,248$547.57+$7.2KMDGEF
2$33,006$13,294.85$12,701$666.53+$20.3KMDGEF
3$57,579$22,261.83$14,405$814.59+$43.2KMDGEF
4$97,904$36,294.48$16,413$999.84+$81.5KMDGEF
5$162,433$57,675.85$18,795$1,232.92+$143.6KMDGEF
6$263,233$89,430.36$21,639$1,527.95+$241.6KMDGEF
7$417,107$135,446.75$25,057$1,903.80+$392.1KMDGEF
8$646,885$200,581.45$29,197$2,385.87+$617.7KMDGEF
9$982,896$290,728.34$34,250$3,008.70+$948.6KMDGEF
10$1,464,540$412,841.82$40,467$3,819.61+$1.42MMDGEF

MDGEF vs EQR: Complete Analysis 2026

MDGEFStock

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Full MDGEF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this MDGEF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDGEF vs SCHDMDGEF vs JEPIMDGEF vs OMDGEF vs KOMDGEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.